Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Emily Chan

6 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCGI1491

07/15/2015

A Double-Blind, Randomised, Placebo Controlled Phase III Study of Nintedanib plus Best Supportive Care (BSC) versus Placebo Plus BSC in Patients with Colorectal Cancer Refractory to Standard Therapies.

Treatment

VICCGI14109

07/01/2015

An Open-Label Expanded Access Study of TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy

Treatment

VICCGI13102

12/09/2014

A Phase II Study of Panitumumab in Combination with FOLFIRI after Progression on FOLFIRI plus Bevacizumab in KRAS and NRAS Wild Type Metastatic Colorectal Cancer

Treatment

VICCGI13114

08/04/2014

A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors

Treatment

VICCGI13101

06/24/2014

Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer

Treatment

VICCGI13100

06/10/2014

A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma